Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability

PR82386

CAMBRIDGE, England, January 6, 2020 /PRNewswire=KYODO JBN/--

Abcam plc, a global innovator in life science reagents and tools, is pleased to

announce the successful completion of the acquisition of Expedeon's Proteomics

and Immunology business, which includes Innova and TGR Biosciences, as of 1st

January 2020. Abcam and Expedeon are fully committed to providing continued

access to Expedeon's proteomics and immunology products and support so that the

life science community can perform their research and development without interruption.

Dr John Baker, SVP Product Portfolio and Innovation, Abcam, commented:

"Our reputation as an innovator in the field of biological reagents, coupled

with our dedicated global commercialisation infrastructure, will allow us to

make these technologies readily available globally. We have had teams working

on conjugation for several years and the combination of this expertise with the

Expedeon portfolio and other complementary conjugation technologies, including

BrickBio's, provides a very powerful platform to enable us to deliver the precision

research tools required to address the majority of life science assays used today

and those emerging in the future."

Protein labelling is essential to biological research in proteomics and 84% of researchers

are looking for conjugation ready solutions[1].  Proteomics research requires the use of

molecular labels that are covalently attached to a protein of interest to facilitate detection

or purification of the protein or its binding partners. With conjugation kits for over 50 types

of labels for applications across the life science industry, Expedeon technology supports

a diverse set of labels, including enzymes, metals, oligos, and fluorescent proteins.

Abcam will combine the newly acquired capture and conjugation technologies with its

extensive antibody and protein expertise to expand and enhance its portfolio of off-the-shelf

and custom reagents and tools.

Notes to Editors

[1] Abcam proprietary data.

About Abcam

As a global life sciences company, Abcam identifies, develops, and distributes

high-quality biological reagents and tools that are crucial to research, drug

discovery and diagnostics. Working across the industry, the Company supports

life scientists to achieve their mission, faster.

Abcam partners with life science organisations to co-create novel binders for

use in drug discovery, in vitro diagnostics and therapeutics, driven by the

Company's proprietary discovery platforms and world-leading, antibody expertise.

By constantly innovating its binders and assays, Abcam is helping advance the

global understanding of biology and causes of disease, which enables new

treatments and improved health. The Company's pioneering data-sharing approach

gives scientists increased confidence in their results by providing validation,

user comments and peer-reviewed citations for its extensive portfolio of over

100,000 products.

With ten sites globally, many of Abcam's 1,100 strong team are located in the

world's leading life science research hubs, complementing a global network of

services and support.

To discover more, please visit www.abcam.com and www.abcamplc.com.

Logo - https://mma.prnewswire.com/media/1061261/Abcam_Logo.jpg

Media Contacts

At Abcam:

Dr Lynne Trowbridge

T: +44 7815 167026

E: lynne.trowbridge@abcam.com

SOURCE: Abcam plc